Medivir’s HCV clinical compound TMC435 attracted considerable attention at this year’s conference of the American Association for the Study of Liver Diseases (AASLD), says Börje Darpö, Medivir’s Vice President for Clinical Development.
Read more »
Forthcoming reports 2009
The Annual Financial Statement will be published on 17 February
The Three-month Interim Report will be published on 23 April
The AGM will be held on 23 April
Medivir’s HCV clinical compound TMC435 attracted considerable attention at this year’s conference of the American Association for the Study of Liver Diseases (AASLD), says Börje Darpö, Medivir’s Vice President for Clinical Development.
